EU’s CHMP Recommends Evusheld by Astrazeneca for Use in Treating COVID-19

Astrazeneca has received a conditional recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its COVID-19 treatment Evusheld. The treatment contains two antibodies against the SARS-CoV-2 virus produced by donated B-cells from people who’ve had COVID-19 in the past.

According to Emily Kimber, “The CHMP’s recommendation is based on results from a phase 3 trial which showed one intramuscular dose of Evusheld provided ‘clinically and statistically significant’ protection against progression to severe COVID-19 or death from any cause compared to placebo.”

To read more, click here.

(Source: PM Live, September 16^th, 2022)